Benoit Vlaminck’s team noted that echinomycin increased HIF-1α activity under normoxia and that it had a dual effect on HIF-1α activity, thus suggesting that the specificity of echinomycin as a cancer therapeutic agent is limited [100]. Here, HIF1A is linked to cancer.